These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10787239)

  • 21. Determination of interactions between human thrombopoietin and its receptor MPL by yeast two-hybrid system and affinity biosensor.
    Hsieh DP; Huxtable S; Ng KF; Chen HM; Tsang PW; Wang J; Xu PP
    Int J Biochem Cell Biol; 2000 May; 32(5):481-8. PubMed ID: 10736563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of thrombopoietin related genes in patients with idiopathic thrombocytopenic purpura].
    Zhang X; Yang Y; Shi H
    Zhonghua Xue Ye Xue Za Zhi; 1998 Nov; 19(11):587-9. PubMed ID: 11263344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombopoietin. A review.
    Baatout S
    Haemostasis; 1997; 27(1):1-8. PubMed ID: 9097080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of thrombopoietin and related Mpl-ligands on transfusion medicine.
    Farese AM; Schiffer CA; MacVittie TJ
    Transfus Med Rev; 1997 Oct; 11(4):243-55. PubMed ID: 9345706
    [No Abstract]   [Full Text] [Related]  

  • 25. Cross-reactivity between erythropoietin and thrombopoietin at the level of Mpl does not account for the thrombocytosis seen in iron deficiency.
    Geddis AE; Kaushansky K
    J Pediatr Hematol Oncol; 2003 Nov; 25(11):919-20; author reply 920. PubMed ID: 14608207
    [No Abstract]   [Full Text] [Related]  

  • 26. In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands.
    Kuter DJ
    Curr Opin Hematol; 1997 May; 4(3):163-70. PubMed ID: 9209831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mpl and the hematopoietic stem cell.
    Kaushansky K
    Leukemia; 2002 Apr; 16(4):738-9. PubMed ID: 11960358
    [No Abstract]   [Full Text] [Related]  

  • 28. c-mpl, the thrombopoietin receptor.
    Vainchenker W; Methia N; Debili N; Titeux M; Wendling F
    Thromb Haemost; 1995 Jul; 74(1):526-8. PubMed ID: 8578519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum but not urine concentration of neutrophil gelatinase-associated lipocalin is influenced by acute leukocyte variations.
    Lippi G; Salvagno GL; Banfi G
    Leuk Lymphoma; 2012 Aug; 53(8):1643-5. PubMed ID: 22263571
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders.
    Duensing S; Duensing A; Meran JG; Kreft A; Büsche G; Ganser A; Georgii A
    Mol Pathol; 1999 Jun; 52(3):146-50. PubMed ID: 10621836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activating mutations of the transmembrane domain of MPL in vitro and in vivo: incorrect sequence of MPL-K, an alternative spliced form of MPL.
    Kitamura T; Onishi M; Yahata T; Kanakura Y; Asano S
    Blood; 1998 Oct; 92(7):2596-7. PubMed ID: 9746805
    [No Abstract]   [Full Text] [Related]  

  • 32. [Thrombopoietin signal transduction via its receptor encoded by c-mpl: its association with hematological diseases].
    Takatoku M; Shimizu R
    Rinsho Ketsueki; 1997 Mar; 38(3):203-8. PubMed ID: 9095659
    [No Abstract]   [Full Text] [Related]  

  • 33. [Regulation of megakaryopoiesis and thrombopoiesis by thrombopoietin].
    Oda A; Ikeda Y
    Rinsho Byori; 1998 May; 46(5):430-4. PubMed ID: 9627493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel MPL point mutation resulting in thrombopoietin-independent activation.
    Abe M; Suzuki K; Inagaki O; Sassa S; Shikama H
    Leukemia; 2002 Aug; 16(8):1500-6. PubMed ID: 12145691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of the MPL receptor in myeloproliferative disorders.
    Kaushansky K
    Leukemia; 1998 Sep; 12 Suppl 1():S47-50. PubMed ID: 9777896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissection of c-Mpl and thrombopoietin function: studies of knockout mice and receptor signal transduction.
    Gurney AL; de Sauvage FJ
    Stem Cells; 1996; 14 Suppl 1():116-23. PubMed ID: 11012211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic effects of thrombopoietin, the Mpl ligand, and its therapeutic potential.
    Papayannopoulou T
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S69-73. PubMed ID: 8765421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding.
    Sabath DF; Kaushansky K; Broudy VC
    Blood; 1999 Jul; 94(1):365-7. PubMed ID: 10381535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genes for thrombopoietin and c-mpl are not responsible for familial thrombocythaemia: a case study.
    Kunishima S; Mizuno S; Naoe T; Saito H; Kamiya T
    Br J Haematol; 1998 Feb; 100(2):383-6. PubMed ID: 9488631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.